Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
CLINICAL UPDATES OF PIMICOTINIB (ABSK021) PRESENTED AT THE 2023 CTOS ANNUAL MEETING

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that two important clinical trial research updates of its self-developed new generation CSF-1R inhibitor pimicotinib (ABSK021) were presented at the 2023 Connective Tissue Oncology Society ("**CTOS**") Annual Meeting held in Ireland from November 1 to 4, 2023. The two tenosynovial giant cell tumor ("**TGCT**") clinical trial updates include reporting the design of the ongoing pivotal global multi-center Phase III clinical trial and a further update of the Phase Ib clinical trial of pimicotinib.

This is a voluntary announcement made by the Company. The Group cannot guarantee that pimicotinib (ABSK021) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, November 3, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Two Important Clinical Trial Research Updates of Pimicotinib (ABSK021) Presented at the 2023 CTOS Annual Meeting

November 3, 2023, Abbisko Therapeutics announced that two important clinical trial research updates of its self-developed new generation CSF-1R inhibitor pimicotinib (ABSK021) were presented at the CTOS Annual Meeting held in Ireland from November 1 to 4, 2023. The two TGCT clinical trial updates include reporting the design of the ongoing pivotal global multi-center Phase III clinical trial and a further update of the Phase Ib clinical trial of pimicotinib.

Upon 1-year follow-up, striking improvement in efficacy has been observed with pimicotinib treatment compared to the 6-month data previously reported at CTOS of last year, with an ORR of 87.5% (28/32, including 3 CR) in the 50 mg QD cohort and 66.7% (8/12, including 2 CR) in the 25 mg QD cohort by IRC based on RECIST 1.1 criteria.

The core points of the wall newspaper presented by Abbisko Therapeutics at this CTOS Meeting are as follows:

Abstract number: 1571943

Title: Updated Efficacy and Safety Profile of Pimicotinib (ABSK021) in Tenosynovial Giant Cell Tumor (TGCT):1 year Follow-up from Phase 1b

Objective: TGCT is a rare class of locally aggressive neoplasm, predominantly driven by overexpression of colony-stimulating factor 1 ("**CSF-1**") gene. Pimicotinib, an orally administered selective small-molecule antagonist of CSF-1R, exhibits minimal inhibition of c-Kit and PDGFR. In 2023, the U.S. FDA conferred Breakthrough Therapy Designation ("**BTD**") and the European Medicines Agency ("**EMA**") granted Priority Medicine Designation ("**PRIME**") upon pimicotinib treatment of TGCT. At the 2023 CTOS Annual Meeting, we report the Phase 1b safety and efficacy results of pimicotinib in TGCT patients over a 1-year follow-up.

Methods: The study (NCT04192344) entailed a TGCT cohort to evaluate the safety and preliminary antitumor activity of pimicotinib in TGCT patients not amenable to surgical resection. The study investigated two dosage regimens: 50 mg once daily (QD) and 25 mg QD.

Results:

1. Clinical characteristics of patients

As of May 31, 2023, a total of 56 TGCT patients were enrolled, comprising 44 patients in the 50 mg QD and 12 patients in the 25 mg QD cohort. Median age was 39 y (range: 18-76) and 41.1% were male. Tumors were primarily located in knee (48.2%), hip (16.1%) or ankle (10.7%). Prior to enrollment, 32 patients (57.1%) had undergone at least one tumor resection surgery.

2. Efficacy Data

A sustained improvement has been observed relative to the 6-month data earlier reported in CTOS last year, with an ORR of 87.5% (28/32, including 3 CR) in 50 mg QD cohort and 66.7% (8/12, including 2 CR) in 25 mg QD cohort by IRC based on RECIST 1.1 (RES). Out of the 16 patients who achieved a PR within the first 6 mos and had follow-up data available, 15 of them (93.8%) sustained this response beyond 6 mos. Out of 5 patients who achieved SD within the first 6 mos and had follow-up data, 4 (80%) patients improved to PR after 6 mos. Median DOR was not reached in either cohort. Durable improvements in range of motion, stiffness and pain over a 1-year follow-up were observed in both dose cohorts.

3. Safety Data

Extended follow-up indicated that pimicotinib was well-tolerated, with a median treatment duration of 12.2 mos and the maximum treatment duration being 17.5 mos. 83.9% patients remained on treatment. The majority of TEAEs were Grade 1 to 2. Most common drug-related TEAEs (≥15%) include LDH increase (80.4%), CPK increase (67.9%), α-HBDH increase (62.5%), AST increase (42.9%), amylase increase (30.4%), ALT increase (25.0%), pruritus (21.4%), rash (19.6%), face oedema (19.6%) and dyslipidaemia (19.6%). No hair color change or serious liver injuries were reported, meanwhile, blood enzymes elevations were asymptomatic, within the expected range, and quickly recovered following drug interruptions, all of which were consistent with previous observations. Compared to the data within 6 mos, the overall safety profile remains largely consistent with no distinct adverse events emerging upon extended follow-up.

Conclusion: Pimicotinib has demonstrated significant anti-tumor efficacy and good safety profile. With the extension of treatment duration, there is an observed augmentation in the number of patients experiencing sustained tumor shrinkage. Current data confers durable therapeutic benefits in TGCT patients, suggesting that prolonged exposure may represent an optimal treatment approach. In addition, a separate cohort with prior anti-CSF-1/CSF-1R therapies is underway to assess the safety and antitumor activity.

Abstract number: 1572315

Title: MANEUVER Study: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Pimicotinib (ABSK021) to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor

Objective:

TGCT is a rare type of locally aggressive neoplasm that is primarily caused by overexpression of CSF-1 gene. Pimicotinib is an oral, highly potent, and selective small-molecule antagonist of CSF-1R with minimum inhibition of c-Kit and PDGFR. In a Phase 1b study, pimicotinib demonstrated significant antitumor activity with the ORR of 77.4% in 50 mg QD cohort by IRC based on RECIST 1.1, and a favorable safety profile (Xu et al, ASCO 2023) in TGCT patients. No apparent ethnic differences were observed for PK and PD data among different ethnic groups based on data from Phase 1 study. Pimicotinib has been granted BTD by China NMPA and US FDA, and PRIME by the EMA for treating TGCT. MANEUVER study (NCT05804045) is a Phase 3, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of pimicotinib at the dose of 50 mg QD in patients with unresectable TGCT. The study marks the first global Phase 3 clinical trial of TGCT patients to be conducted simultaneously across Asia, North America and Europe.

Study Design

MANEUVER study consists of two parts. Part 1 is a double-blind phase, approximately 90 eligible patients will be randomized in a 2:1 ratio to pimicotinib treatment group or matching placebo group and will receive 50mg QD pimicotinib treatment or matching placebo treatment under double-blind conditions until the completion of Part 1. The randomization will be stratified by geographical location, China vs. non-China sites. All patients who complete Part 1 and meet eligibility criteria will proceed to Part 2.

In Part 2, open-label treatment phase, all patients entering this phase will receive open-label 50 mg QD of pimicotinib until the completion of 24 weeks of dosing or withdrawal from the study. Patients who complete 24 weeks of dosing in Part 2 may be eligible for extended treatment.

Study Endpoints:

The primary endpoint is 25-week ORR by Blinded Independent Review Committee ("**BRIC**") based on RECIST 1.1. Key secondary endpoints comprise 25-week ORR by BIRC based on Tumor Volume Score, the mean change from baseline in Range of Motion of the affected joint at week 25, the mean change from baseline in the Worst Stiffness and Worst Pain NRS score at week 25, and the mean change from baseline in the PROMIS Physical Functioning score at week 25.

Study Population:

Key inclusion criteria include patients that are: 1) histologically confirmed TGCT and not amenable to surgical resection; 2) existing measurable disease based on RECIST 1.1; 3) willingness and ability to complete PRO assessments; 4) symptomatic disease (based on level of pain and stiffness); and 5) age of 18 or older. Key exclusion criteria include : 1) previous treatment with highly selective inhibitors targeting CSF-1/CSF-1R (Imatinib and Nilotinib are allowed); 2) known metastatic TGCT or MRI contraindications; and 3) major surgery or previous anti-tumor therapy of TGCT within 4 weeks prior to randomization. An Independent Data Monitoring Committee (IDMC) will be established to continuously monitor the safety profile and oversee the overall conduct of the trial.

Results:

Enrollment is ongoing, approximately 40 sites around the world will participate in this study.

Conclusion: Not applicable

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology, including 8 clinical stage assets.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.